NCT04540393 - AZD1222 Vaccine for the Prevention of COVID-19 | Biotech Hunter

Timeline

Start Date

September 2, 2020

Primary Completion Date

December 4, 2020

Study Completion Date

May 11, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

AZD1222

Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) \> 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection

Trial Locations (4)

117321

Research Site, Moscow

196240

Research Site, Saint Petersburg

197022

Research Site, Saint Petersburg

197376

Research Site, Saint Petersburg